Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Open accessThe DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Abstract
Pain is common in cancer patients, particularly in the advanced stage of disease when the prevalence is estimated to be more than 70% [1], contributing to poor physical and emotional well-being. The most comprehensive systematic review indicates pain prevalence ranging from 33% in patients after curative treatment, to 59% in patients on anticancer treatment and to 64% in patients with metastatic, advanced or terminal disease [2]. Pain has a high prevalence earlier in disease in specific cancer types such as pancreatic (44%) and head and neck cancer (40%) [3].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 2 The assessment of BTcP. BTcP, breakthrough cancer pain. Reprinted with permission from [116].](https://figures.cochat.ai/paper-figures/ca72788a69f549f1926fbf99429f0118/management-of-cancer-pain-in-adult-patients-esmo-clinical-practice-guidelines-figure-2.png)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the recent ESMO guidelines106 are difficult to follow in those countries where the majority of patients experiencing cancer pain live.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [106]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Treede (2008) · doi:10.1212/01.wnl.0000282763.29778.59 · Cited by 2,746
Opioid Complications and Side Effects
Benyamin, R. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/s105 · Cited by 2,245
Pain and Its Treatment in Outpatients with Metastatic Cancer
Cleeland, C. S., Gonin, R., Hatfield, A. K., Edmonson, J. H., Blum, R. H., Stewart, J. A., & Pandya, K. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300902 · Cited by 2,019
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Prevalence of pain in patients with cancer: a systematic review of the past 40 years
van den Beuken-van Everdingen, M. H. J., de Rijke, J. M., Kessels, A. G., Schouten, H. C., van Kleef, M., & Patijn, J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm056 · Cited by 1,923
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Knaul, F. M., Farmer, P. E., Krakauer, E. L., De Lima, L., Bhadelia, A., Jiang Kwete, X., Arreola-Ornelas, H., Gómez-Dantés, O., Rodriguez, N. M., Alleyne, G. A. O., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32513-8 · Cited by 1,456
Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70040-2 · Cited by 1,243
Self-citation
Cited by
Items 101–200 of 954
Doppenberg-Smit, G. E., Lamers, F., Linde, M. E. V., Braamse, A. M. J., Sprangers, M. A. G., Beekman, A. T. F., Verheul, H. M. W., & Dekker, J. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-024-01543-0 · Cited by 31
“Examples include nausea, lack of appetite, and pain [10, 11].”
Intrathecal therapy for pain in cancer patients
Dupoiron, D. (2019) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000427 · Cited by 25
Hamano, J., Higashibata, T., Kessoku, T., Kajiura, S., Hirakawa, M., Oyamada, S., Ariyoshi, K., Yamada, T., Yamamoto, Y., Takashima, Y., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00381 · Cited by 24
Opening up disruptive ways of management in cancer pain: the concept of multimorphic pain
Lemaire, A., George, B., Maindet, C., Burnod, A., Allano, G., & Minello, C. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04831-z · Cited by 27
Zhang, L., McLeod, H. L., Liu, K.-K., Liu, W., Huang, H., Huang, Y.-M., Sun, S., Chen, X., Chen, Y., Liu, F.-Z., et al. (2021) · JMIR mhealth and uhealth · doi:10.2196/24555 · Cited by 27
Targeting TRPV1 for Cancer Pain Relief: Can It Work?
SZALLASI, A. (2024) · Cancers · doi:10.3390/cancers16030648 · Cited by 30
Prevalence of opioid misuse in patients with cancer: a systematic review and meta-analysis
Ako, T., Oernskov, M. P., Lykke, C. C., Sjøgren, P., & Kurita, G. P. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02802-8 · Cited by 26
“These discrepancies underscore the need for more studies with standardised de fi nitions, validated assessment instruments, cohesive research strategies, and well-described guidelines to accurately quantify and address this issue within patients with cancer.”
BackgroundMantoudi, A., Parpa, E., Tsilika, E., Batistaki, C., Nikoloudi, M., Kouloulias, V., Kostopoulou, S., Galanos, A., & Mystakidou, K. (2020) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2019.0402 · Cited by 23
Molecular targets in bone cancer pain: a systematic review of inflammatory cytokines
Ruivo, J., Tavares, I., & Pozza, D. H. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02464-2 · Cited by 28
“In addition, other adjuvant therapies including antiepileptics, steroids, antidepressants, radiotherapy, nerve blocks, nerve lesions, and surgery are often used to control cancer pain [4, 7, 8].”
BackgroundWang, Z., Sun, J., Sun, Y., Gu, Y., Xu, Y., Zhao, B., Yang, M., Yao, G., Zhou, Y., Li, Y., et al. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00251-2 · Cited by 22
“Breakthrough cancer pain (BTcP) is defined as ‘‘a transitory flare of pain that occurs on a background of relatively well-controlled baseline pain’’ [29].”
BackgroundBibliometric Analysis of Acupuncture Therapy for Cancer Pain Over the Past 10 Years
Ling, F., Qi, W., Li, X., Zhou, J., Xiong, J., Zhao, Y. D., Zheng, Q., & Liang, F. (2023) · Journal of Pain Research · doi:10.2147/jpr.s395421 · Cited by 26
Marinelli, D., Giusti, R., Mazzotta, M., Filetti, M., Krasniqi, E., Pizzuti, L., Landi, L. M., Tomao, F., Cappuzzo, F., Ciliberto, G., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103176 · Cited by 19
Self-citationHamedi, V., Hamid, N., Beshlideh, K., Marashi, S. A., & Shabani, S. E. H. S. (2020) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs.83110 · Cited by 24
“The therapeutic package was designed based on the articles (8-14) in this area and the content of the handbook of Pain Management (37).”
BackgroundMethodUnderstanding the Chameleonic Breakthrough Cancer Pain
Mercadante, S., & Portenoy, R. K. (2021) · Drugs · doi:10.1007/s40265-021-01466-5 · Cited by 21
“Notwithstanding these observations, the National Institute for Clinical Excellence (NICE) and recent WHO guidelines suggest that morphine should be considered the first-choice drug for BTcP [38], Similarly, ESMO guidelines position oral morphine in predictable breakthrough pain [39].”
BackgroundEffectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation
Lemaire, A., Pointreau, Y., Narciso, B., Piloquet, F., Braniste, V., & Sabaté, J. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06299-2 · Cited by 25
Han, C., Liu, Y., Fan, H., Li, D., & Guo, N. (2021) · Clinical Epidemiology · doi:10.2147/clep.s324193 · Cited by 21
“About 30–70% of cancer patients experience pain during all stages of the disease, such as anticancer treatment, curative treatment, and life-long treatment.(1) Opioid analgesia is a frequently used medicine and is one of the most effective pain relief drugs.”
BackgroundClinical Decision Support for Symptom Management in Lung Cancer Patients: A Group RCT
Cooley, M. E., Mazzola, E., Xiong, N., Hong, F., Lobach, D. F., Braun, I. M., Halpenny, B., Rabin, M. S., Johns, E., Finn, K. T., et al. (2021) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2021.12.006 · Cited by 23
Huerta, M. Á., de la Nava, J., Artacho-Cordón, A., & Nieto, F. R. (2023) · Marine Drugs · doi:10.3390/md21050316 · Cited by 29
Interventional pain management in cancer patients—a scoping review
Habib, M. H., Schlögl, M., Raza, S., Chwistek, M., & Gulati, A. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-23-433 · Cited by 26
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., & Khosravi‐Shahi, P. (2020) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2020.06.026 · Cited by 23
Cascella, M., Crispo, A., Esposito, G., Forte, C. A., Coluccia, S., Porciello, G., Amore, A., Bimonte, S., Mercadante, S., Caraceni, A. T., et al. (2021) · Cancers · doi:10.3390/cancers13164018 · Cited by 23
“In the same guidelines, morphine received a level of evidence of II and a degree of recommendation of B [20].”
BackgroundLudwig, H., Bailey, A., Marongiu, A., Khela, K., Milligan, G., Carlson, K., Rider, A., & Seesaghur, A. (2021) · Cancer Reports · doi:10.1002/cnr2.1429 · Cited by 30
“Pain is a common debilitating symptom of cancer and contributes to poor health-related quality of life (HRQoL).(1) Patients with multiple myeloma (MM), especially those with relapsed/refractory disease, experience significantly more pain and poorer HRQoL (including physical, role, emotional, and social functioning) co…”
BackgroundYu, Z., Li, W., Shangguan, X., Cai, Y., Gao, Q., Wang, X., Chen, Y., Liu, D., & Zhang, C. (2022) · Journal of Pain Research · doi:10.2147/jpr.s339377 · Cited by 26
Treating persistent pain after breast cancer: practice gaps and future directions
Groef, A. D., Meeus, M., Heathcote, L. C., Wiles, L., Catley, M. J., Vogelzang, A. R., Olver, I., Runciman, W. B., Hibbert, P. D., Dams, L., et al. (2022) · Journal of Cancer Survivorship · doi:10.1007/s11764-022-01194-z · Cited by 26
Breathing Exercises for Pain Management in Cancer Survivors: A Systematic Review
Wang, H., Liu, X., Wang, T., Tan, J.-Y. B., & Huang, H. (2022) · Pain Management Nursing · doi:10.1016/j.pmn.2022.11.003 · Cited by 28
Medical Cannabis: A Review from the American Society of Pain and Neuroscience
Strand, N. H., D'Souza, R. S., Karri, J. V., Kalia, H., Weisbein, J. S., Kassa, B. J., Hussain, N., Chitneni, A., Budwany, R. R., Hagedorn, J. M., et al. (2023) · Journal of Pain Research · doi:10.2147/jpr.s425862 · Cited by 27
“62 The most robust supporting evidence for treatment of cancer-related pain with CBPs is derived from 2 large randomized controlled trials that reported superiority of nabiximols vs placebo for treating cancer pain that is refractory to opioid therapy.”
BackgroundEpigenetic mechanisms of bone cancer pain
Ni, C., Chen, L., Hua, B., Han, Z., Xu, L., Zhou, Q., Yao, M., & Ni, H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110164 · Cited by 28
“…Zajaczkowska et al., 2019), may lead to the development of depression and anxiety, reduced appetite, decreased sleep quality, and limited social activities, significantly impairing patients ’ quality of life (Fallon et al., 2018; van den Beuken-van Everdingen et al., 2016; Yoneda et al., 2023).”
BackgroundExpert consensus on the management of breakthrough cancer pain in older patients. A Delphi study
Alarcón, M. D. L., Estévez, F. V., Cabezón‐Gutiérrez, L., Padrós, M. R. C., Martín-Arroyo, J. M. T., Rebollo, M. A., López, A. J. J., & Sanz-Yagüe, A. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.03.012 · Cited by 20
Opioid use in cancer patients compared with noncancer pain patients in a veteran population
Mudumbai, S. C., He, H., Chen, J.-Q., Kapoor, A., Regala, S., Mariano, E. R., Stafford, R. S., Abnet, C. C., Pfeiffer, R. M., Freedman, N. D., et al. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae012 · Cited by 19
Cascella, M., Gennaro, P. D., Crispo, A., Vittori, A., Petrucci, E., Sciorio, F., Marinangeli, F., Ponsiglione, A. M., Romano, M., Ovetta, C., et al. (2024) · BMC Palliative Care · doi:10.1186/s12904-024-01526-z · Cited by 21
“Furthermore, an even larger percentage, potentially reaching 70%, of those facing advanced or terminal illnesses, experience pain [1, 2].”
BackgroundTang, Y., Chen, H., Zhou, Y., Tan, M., Xiong, S., Li, Y., Ji, X., & Li, Y.-S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.840855 · Cited by 23
“Meanwhile, there were also some other treatments for cancer pain, such as radiotherapy, surgery, chemotherapy, radioisotope therapy, bisphosphonate and so on (8).”
BackgroundContribution of immune cells to cancer-related neuropathic pain: An updated review
Ma, H., Pan, Z., Lai, B., Li, M., & Wang, J. (2023) · Molecular Pain · doi:10.1177/17448069231182235 · Cited by 21
“Notably, cancer-related neuropathic pain shares most of common clinical features with classical neuropathic pain, include shooting, sharp, stabbing, tingling, pricking, electric shocks and pins as well as needles.(45) However, it is increasingly recognised that neuropathic pain actually comprises a range of different…”
BackgroundTetrahydrocannabinol and Cannabidiol for Pain Treatment—An Update on the Evidence
Safi, K., Sobieraj, J., Błaszkiewicz, M., Żyła, J., Salata, B., & Dzierżanowski, T. (2024) · Biomedicines · doi:10.3390/biomedicines12020307 · Cited by 27
“…what continues to make cannabinoids an attractive option for researchers is the absence of respiratory depression, allowing their combined administration with opioids for synergistic effect, as well as successful pain relief in chemotherapy-induced peripheral neuropathy (CIPN) in animal models [5].”
BackgroundSouth African guidelines for receptor radioligand therapy (RLT) with Lu-177-PSMA in prostate cancer
Vorster, M., Warwick, J., Lawal, I. O., du Toit, P. D., Vangu, M. D. T. H. W., Nyakale, N., Steyn, R., Gutta, A., Hart, G., Mutambirwa, S. B. A., et al. (2019) · South African Journal of Surgery · doi:10.17159/2078-5151/2019/v57n4a3107 · Cited by 18
Villegas, F., Martínez‐Borba, V., Suso‐Ribera, C., Castilla, D., Zaragozá, I., García‐Palacios, A., & Albiach, C. F. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18115991 · Cited by 24
Psychedelics in the Treatment of Headache and Chronic Pain Disorders
Schindler, E. A. D. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_365 · Cited by 20
Leucht, K., Ali, N., Foller, S., & Grimm, M. (2022) · Cancers · doi:10.3390/cancers14184369 · Cited by 25
Pain management in patients with malignant mesothelioma: challenges and solutions
Saunders, J. H., Ashton, M., Hall, C. C., Laird, B. J. A., & MacLeod, N. J. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s192558 · Cited by 20
“This registry has recorded over 200 cases prospectively, including the safety and efficacy of this technique.(36)”
BackgroundMethodInfluentialThe role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients
Brząkała, J. M., & Leppert, W. (2019) · Pharmacological Reports · doi:10.1016/j.pharep.2019.01.010 · Cited by 18
Guidelines for Rational Clinical Use of Fentanyl Transdermal Patch
Fu, Q., Han, N., Li, N., Gui, L., Shi, C., Rong, P., Zeng, F., Rao, H. A., & Chen, Y. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s414318 · Cited by 19
“21 To this end, fentanyl is significantly metabolized in the liver, and the resultant norfentanyl metabolite has no biological activity.”
Chang, J., Liu, L., Wang, Y., Sui, Y., Li, H., & Li, F. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/7617261 · Cited by 20
“In the first stage of three-step pain relief, it achieved the purpose of pain relief by inhibiting the target and cyclooxygenase pathway [2].”
BackgroundAutrusseau, P.-A., Cazzato, R. L., Marini, P. D., Auloge, P., Koch, G., Dalili, D., Weiss, J., Mayer, T., Garnon, J., & Gangi, A. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.05.013 · Cited by 17
Leppert, W., Zajączkowska, R., & Wordliczek, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561863 · Cited by 17
Reis-Pina, P., Sabri, E., Birkett, N., Barbosa, A., & Lawlor, P. G. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.06.017 · Cited by 20
Yamamoto, P. A., Costa, A., Lauretti, G. R., & de Moraes, N. V. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0066 · Cited by 23
Norris, B. A., Smith, A., Doran, S., & Barry, M. G. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5247 · Cited by 17
“erate to severe pain in the WHO Cancer Pain Relief Guidelines and is cited as the opioid of first choice in renowned clinical guidelines.(17,19,42) The low level of morphine prescribing relative to other strong opioids mirrors trends in other EU countries.”
BackgroundHung, H.-Y., Chien, W., Chung, C., Kao, L., Chow, L., Chen, Y.-H., Kotlinska, J. H., Silberring, J., & Huang, E. Y. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109102 · Cited by 21
Central Sensitization in Cancer Survivors and Its Clinical Implications: State of the Art
Nishigami, T., Manfuku, M., & Lahousse, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144606 · Cited by 25
Prologo, J. D., Manyapu, S. R., Bercu, Z. L., Mittal, A., & Mitchell, J. W. (2020) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909119892003 · Cited by 16
“For these patients, consideration of invasive techniques for pain control is considered appropriate.(14) The use of cryoablation to target nerves for the treatment of painful conditions has existed for more than 50 years.”
Nonopioid drug combinations for cancer pain: a systematic review
Sohi, G. K., Lao, N., Caraceni, A., Moulin, D. E., Zimmermann, C., Herx, L., & Gilron, I. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000995 · Cited by 22
Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention
Buonaiuto, R., Neola, G., Cecere, S. C., Caltavituro, A., Cefaliello, A., Pietroluongo, E., Placido, P. D., Giuliano, M., Arpino, G., & Angelis, C. D. (2023) · Biomolecules · doi:10.3390/biom13040653 · Cited by 18
Zeng, X., Zhu, J., Li, J., Chen, C., Sang, L., Liu, M., Song, L., & Liu, H. (2023) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2023.09.018 · Cited by 17
Gupta, S., Li, Q., Kassam, A., Rapoport, A., Widger, K. A., Chalifour, K., Baxter, N. N., Nathan, P. C., Coburn, N. G., & Sutradhar, R. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.38699 · Cited by 18
Polysaccharides: New Frontiers for Nasal Administration of Medicines
Clementino, A., Climani, G., Bianchera, A., Buttini, F., & Sonvico, F. (2025) · Polysaccharides · doi:10.3390/polysaccharides6010006 · Cited by 21
“BTCP, according to a study presented at ESMO 2018, has an estimated prevalence of 59% and is present in 39% of outpatient cases and 80% of hospitalized patients [66].”
Millard, S. K., & de Knegt, N. C. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.07.013 · Cited by 18
Bao, Y., Zhang, H., Bruera, E. D., Portenoy, R. K., Rosa, W. E., Reid, M. C., & Wen, H. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5623 · Cited by 17
Best Supportive Care of the Patient with Oesophageal Cancer
Pichel, R. C., Araújo, A., Domingues, V. D. S., Santos, J. N., Freire, E., Mendes, A. S., Romão, R., & Araújo, A. (2022) · Cancers · doi:10.3390/cancers14246268 · Cited by 19
Slotman, D. J., Bartels, M., Ferrer, C. J., Bos, C., Bartels, L. W., Boomsma, M. F., Phernambucq, E. C. J., Nijholt, I. M., MORGANTI, A. G., SIEPE, G., et al. (2022) · Trials · doi:10.1186/s13063-022-06942-1 · Cited by 15
Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases
Inagaki, F. F., Wakiyama, H., Furusawa, A., Okada, R., Kato, T., Fujimura, D., Okuyama, S., Fukushima, H., Takao, S., Choyke, P. L., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114390 · Cited by 15
Exploring Biosignals for Quantitative Pain Assessment in Cancer Patients: A Proof of Concept
Cascella, M., Vitale, V. N., D’Antò, M., Cuomo, A., Amato, F., Romano, M., & Ponsiglione, A. M. (2023) · Electronics · doi:10.3390/electronics12173716 · Cited by 18
Advancing Postoperative Pain Management in Oral Cancer Patients: A Systematic Review
Inchingolo, A. M., Dipalma, G., Inchingolo, A. D., Palumbo, I., Guglielmo, M., Morolla, R., Mancini, A., & Inchingolo, F. (2024) · Pharmaceuticals · doi:10.3390/ph17040542 · Cited by 24
“…persistent or initially moderate-to-severe pain, an escalation For persistent or initially moderate-to-severe pain, an escalation in opioid potency (mainly morphine, methadone, or fentanyl) is recommended [66–68]. in opioid potency (mainly morphine, methadone, or fentanyl) is recommended [66–68].”
BackgroundThe Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine
Skórzewska, M., & Gęca, K. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01589-4 · Cited by 20
“Other phase three trials echoed these findings, with Nabiximols showing no distinct advantage as a co-analgesic in high opioid-requiring cancer patients [42].”
Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?
Lord, S., Hardy, J. R., & Good, P. D. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00934-0 · Cited by 15
A clinical approach to the management of cancer-related pain in emergency situations
Burnod, A., Maindet, C., George, B., Minello, C., Allano, G., & Lemaire, A. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04830-0 · Cited by 17
Savaş, M., Bayraktar‐Ekincioglu, A., & Çelebi, N. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01098-x · Cited by 15
Research progress on the impact of opioids on the tumor immune microenvironment (Review)
Zhou, Y., Li, W., Chen, Y., Hu, X., & Miao, C. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2848 · Cited by 16
Reed, D. E., Cobos, B. A., Nabity, P. S., Doolin, J., & McGeary, D. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-72216-2.00015-6 · Cited by 17
Duarte, R. V., Sale, A., Desai, P., Marshall, T., & Eldabe, S. S. (2020) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.13264 · Cited by 14
“In line with the NHS England policy, the use of ITDD as part of a cancer management strategy for patients with limited life expectancy as well as those patients with near normal life expectancy also has been recommended by the recent European Society for Medical Oncology (ESMO) clinical practice guidelines (10).”
MethodDai, L., Liu, Y., Ji, G., & Xu, Y. (2021) · Journal of Palliative Medicine · doi:10.1089/jpm.2020.0405 · Cited by 18
Franco, J., de Souza, R. N., Lima, T. D. M., Moriel, P., & Visacri, M. B. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211073470 · Cited by 17
“Another guideline that may be used is the European Society for Medical Oncology (ESMO) Clinical Practice Guideline for cancer pain management.(38) In the study by Yamada et al.”
Yu, X., Li, Z., & Song, B. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02210-9 · Cited by 15
Porzio, G., Capela, A., Giusti, R., Bianco, F. L., Moro, M., Ravoni, G., & Żułtak-Bączkowska, K. (2023) · Drugs in Context · doi:10.7573/dic.2022-11-7 · Cited by 15
Self-citationCancer Pain Experience Through the Lens of Patients and Caregivers: Mixed Methods Social Media Study
Filipponi, C., Chichua, M., Masiero, M. A., Mazzoni, D., & Pravettoni, G. (2023) · JMIR Cancer · doi:10.2196/41594 · Cited by 15
The role of cancer nurses in cancer-related pain management in Europe
Munter, J. D., Dodlek, N., Khmaladze, A., Parreira, S. T., Ullgren, H., de Man, R., de Jong, F. A., & Oldenmenger, W. H. (2023) · Palliative Care and Social Practice · doi:10.1177/26323524231216996 · Cited by 38
“9,14,17 The best known and most widely used unidimensional tools for responsive patients are the numeric rating scale, the visual analogue scale and verbal rating scale.”
MethodOpioid metabolism and drug-drug interaction in cancer
Aapro, M., Fogli, S., Morlion, B. J., & Danesi, R. (2024) · The Oncologist · doi:10.1093/oncolo/oyae094 · Cited by 14
Fernandes, M., Schelotto, M., Doldi, P. M., Milani, G., Manzano, A. A. A., Valdivia, D. P., Winter-Matos, A., Abdelrahim, Y. H., Bek, S. A. H., Benitez, B. K., et al. (2021) · F1000Research · doi:10.12688/f1000research.27809.1 · Cited by 14
Quinn, B. G., Ludwig, H., Bailey, A., Khela, K., Marongiu, A., Carlson, K. B., Rider, A., & Seesaghur, A. (2021) · Pain Management · doi:10.2217/pmt-2021-0013 · Cited by 14
Current management of cancer pain in Italy: Expert opinion paper
Marinangeli, F., Saetta, A., & Lugini, A. (2021) · Open Medicine · doi:10.1515/med-2021-0393 · Cited by 14
“The guidelines [31,57,59] recommend prescribing the lowest initial dose of immediate release opioids to patients who are started with opioids; oxycodone or hydromorphone, both have immediate-release and modified-release formulations for oral administration, are effective alternatives to oral morphine in moderate to se…”
BackgroundInfluentialA new therapeutic approach for bone metastasis in colorectal cancer: intratumoral melittin
Rocha, M. M., Dariva, I., Zornoff, G. C., Laurentis, G. S. D., Mendes, G. C., Santana, M. G., de Miguel, G. C. D. G. C., Junior, R. S. F., Sciani, J. M., & Priolli, D. G. (2022) · The Journal of venomous animals and toxins including tropical diseases · doi:10.1590/1678-9199-jvatitd-2021-0067 · Cited by 14
Janah, A., Bouhnik, A., Touzani, R., Bendiane, M., & Peretti‐Watel, P. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.10.027 · Cited by 16
“In addition, cancer-related treatments, such as chemotherapy, would be one of the leading causes of iatrogenic pain and painful neuropathy for example, which may partly explain why survivors who undergo chemotherapy have been prescribed more opioids (step III in particular) (35).”
BackgroundEpidemiology of Resistant Cancer Pain: Prevalence, Clinical Burden, and Treatment Gaps
McLean, A. L., Kahr, J., Régis, J. M., Kamp, M. A., & Senft, C. (2025) · Stereotactic and Functional Neurosurgery · doi:10.1159/000547446 · Cited by 24
Creangă-Murariu, I., Rezuş, I.-I., Karami, R., Rancz, A., Zolcsák, Á., Engh, M. A., Obeidat, M., Tamba, B.-I., Hegyi, P., & Bunduc, Ș. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01695-x · Cited by 19
Incidence of Delirium With Different Oral Opioids in Previously Opioid-Naive Patients
Sugiyama, Y., Tanaka, R., Sato, T., Sato, T., Saitoh, A., Yamada, D., & Shino, M. (2022) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091211065171 · Cited by 13
Matsangidou, M., Kassianos, A. P., Papaioannou, D., Solomou, T., Krini, M., Karekla, M., & Pattichis, C. S. (2022) · CHI Conference Extended Abstracts on Human Factors in Computing Systems (CHI EA) · doi:10.1145/3491101.3503562 · Cited by 13
“Timely evaluations of pain intensity, worst pain occurrence and functionality impairments are considered of vast importance, as this can inform healthcare professionals on the pain patterns which can subsequently lead to adequate treatment [33].”
BackgroundVarrassi, G., Coluzzi, F., Fornasari, D., Fusco, F., Gianni, W., Guardamagna, V. A., Puntillo, F., & Sotgiu, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247451 · Cited by 13
Bulls, H. W., Hamm, M., Wasilko, R., Cameron, F. D. A., Belin, S. C., Goodin, B. R., Liebschutz, J. M., Wozniak, A. J., Sabik, L. M., Schenker, Y., et al. (2023) · Journal of Pain · doi:10.1016/j.jpain.2023.01.015 · Cited by 15
Should oncologists trust cannabinoids?
Creangă-Murariu, I., Filipiuc, L.-E., Cuciureanu, M. D., Tamba, B.-I., & Alexa‐Stratulat, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1211506 · Cited by 13
“Furthermore, there is need for further double-blind, placebocontrolled clinical trials with large sample size in order to establish proper indications (Fallon et al., 2018).”
BackgroundResultInfluentialEfficacy of epidural analgesia for intractable cancer pain: A systematic review
Hsieh, Y., Chen, H., Lin, C., & Wang, C. Y. (2023) · Pain Practice · doi:10.1111/papr.13273 · Cited by 15
“5 A systematic review published in 2015, including nine RCTs, demonstrated that the quality of evidence for neuraxial analgesia on cancer-related pain was very low.”
BackgroundBang, Y. H., Choi, Y. H., Park, M.-C., Shin, S.-Y., & Kim, S. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-37742-5 · Cited by 13
“As there was no quantitative consensus on the definition of CPE, we defined CPE as an NRS score of 4, a commonly used indication of opioid intervention in cancer pain management guideline[2].”
Zhu, H., Lin, R., Wang, J., Ruan, S., Hu, T., Yan, L., Ke, X., & Luo, H.-Y. (2024) · BMJ Open · doi:10.1136/bmjopen-2022-071417 · Cited by 16
Update on musculoskeletal applications of magnetic resonance-guided focused ultrasound
McGill, K. C., Baal, J. D., & Bucknor, M. D. (2024) · Skeletal Radiology · doi:10.1007/s00256-024-04620-8 · Cited by 13
“Currently, the standard palliative treatment for painful bone metastases includes analgesics, including opioid medications, and noninvasive procedures like external beam radiation therapy (EBRT) [15].”
BackgroundRepetitive Transcranial Magnetic Stimulation: Is it an Effective Treatment for Cancer Pain?
Du, Y., Li, Y., Hu, J., Fang, R., Liu, Y., Cai, L., Song, Y., Ma, S., Gao, J., Zhang, H., et al. (2024) · Pain and Therapy · doi:10.1007/s40122-024-00679-2 · Cited by 14
Suga, Y., Uchida, M., Suzuki, S., Sugawara, H., Torigoe, K., Futamura, A., Uesawa, Y., Nakagawa, T., & Takase, H. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00997 · Cited by 13
Camps, C., Antón, A., Cruz, J. J., Carrato, A., Constenla, M., Díaz‐Rubio, E., Feyjóo, M., García‐Foncillas, J., Gascón, P., & Guillém, V. (2019) · Journal of Pain Research · doi:10.2147/jpr.s203903 · Cited by 13
Managing Pain in the Older Cancer Patient
Finnerty, D. T., O’Gara, Á., & Buggy, D. J. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0854-7 · Cited by 14
Hui, D., Abdelghani, E., Chen, J., Dibaj, S., Zhukovsky, D. S., Dev, R., Tanco, K. C., Haider, A., Azhar, A., Reddy, A. S., et al. (2020) · Cancers · doi:10.3390/cancers12010214 · Cited by 15
Ouyang, R., Li, Z., Huang, S., Liu, J., & Huang, J. (2020) · Pain Medicine · doi:10.1093/pm/pnaa152 · Cited by 13
Effectiveness of Superior Hypogastric Plexus Neurolysis for Pelvic Cancer Pain
Hernández-Porras, B. C. (2020) · Pain Physician · doi:10.36076/ppj.2020/23/203 · Cited by 13
Topical Fixed-Dose Combinations: A Way of Progress for Pain Management?
Veloso, C., Cardoso, C., & Vitorino, C. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.06.009 · Cited by 13
Huang, Y., Roy, N., Dhar, E., Upadhyay, U., Kabir, M. A., Uddin, M., Tseng, C., & Syed-Abdul, S. (2023) · Cancers · doi:10.3390/cancers15082232 · Cited by 16
Metadata
- Authors
- Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I.
- Affiliations
- Edinburgh Cancer Research (GB)
- Azienda Ospedaliera Sant'Andrea (IT)
- University of L'Aquila (IT)
- Mount Vernon Cancer Centre (GB)
- RWTH Aachen University (DE)
- Walton Centre (GB)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 29
- Issue
- Suppl 4
- Pages
- iv166-iv191
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2834719472
- Cited by
- 954
- References
- 184
- Citations by year
- 2026: 136 · 2025: 140 · 2024: 143 · 2023: 123 · 2022: 129 · 2021: 126 · 2020: 88 · 2019: 61 · 2018: 6
- FWCI
- 103.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 463 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, other-oa)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- Marie Curie (MCCC-RP-12-A14197, MCCC-RP-15-A18862, MCCC-RP-15-A19005)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pediatric Pain Management Techniques
- Keywords
- cancer pain, pain management, advanced cancer, metastatic cancer, terminal cancer, pain prevalence, palliative care, analgesia
- MeSH terms
- Cancer Pain, Cancer Survivors, Pain, Procedural, Procedural Pain, Adult, Analgesics, Opioid, Antineoplastic Combined Chemotherapy Protocols, Europe, Humans, Medical Oncology, Neoplasm Staging, Neoplasms, Pain Measurement, Societies, Medical, Terminal Care, Prevalence, Treatment Outcome, Breakthrough Pain, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.